10 Pharma CEOs Shaping the Industry’s Next Era

The leaders of today’s largest pharmaceutical companies come from diverse backgrounds spanning science, medicine, finance, diagnostics, operations and commercial leadership. Yet their priorities are strikingly similar: investing in oncology, obesity and metabolic disease, neuroscience, rare diseases, advanced biologics and next-generation therapeutic platforms. For CDMOs, the strategic decisions made by these executives will continue to shape outsourcing trends, manufacturing investments, supply-chain strategies and partnership opportunities throughout the global pharmaceutical industry.

The following is an overview of the careers, tenures and major accomplishments of the CEOs of the top 10 global pharma and biopharma companies from Lilly to Novo Nordisk.

1. David A. Ricks

Chair and CEO, Eli Lilly and Company

CEO since: 2017

Why He Matters

Since becoming CEO in 2017, David A. Ricks has transformed Eli Lilly and Company into one of the pharmaceutical industry’s most successful growth stories. His tenure has been defined by breakthrough obesity and diabetes therapies, significant pipeline expansion and some of the largest manufacturing investments in the sector.

Career Path

Ricks joined Lilly in 1996 as a business development associate and advanced through leadership positions in sales, marketing, business development and international operations. He led Lilly’s businesses in Canada and China, served as president of Lilly USA, and later headed Lilly Bio-Medicines before becoming CEO in January 2017 and chairman later that year.

At a Glance

Background: Commercial operations, business development, international leadership
Strategic focus: Obesity, diabetes, neuroscience, manufacturing expansion

Key Achievements

• Led the launch of Mounjaro (2022) and Zepbound (2023), establishing Lilly as a leader in obesity and diabetes treatment.
• Oversaw more than $18 billion in manufacturing investments across the U.S. and Europe.
• Expanded Lilly’s neuroscience and immunology pipelines while delivering record R&D productivity.
• Positioned Lilly among the world’s most valuable pharmaceutical companies through the success of tirzepatide.

Why Contract Pharma Readers Should Care

Lilly’s manufacturing buildout, obesity-drug demand, and growing biologics footprint are creating substantial opportunities across the CDMO and pharmaceutical supply chain sectors.

---

2. Robert M. Davis

CEO and Chairman, Merck & Co.

CEO since: 2021

Why He Matters

Robert M. Davis is leading Merck through one of the industry’s most closely watched transitions: maintaining the momentum of Keytruda while preparing for the blockbuster’s eventual loss of exclusivity.

Career Path

Davis joined Merck as chief financial officer in 2014 after leadership positions at Baxter and Eli Lilly. He became president in 2021, CEO later that year, and chairman in 2022.

At a Glance

Background: Finance, strategy, operations
Strategic focus: Oncology diversification, cardiovascular disease, business development

Key Achievements

• Expanded Merck’s post-Keytruda strategy through acquisitions including Acceleron, Prometheus Biosciences, and Harpoon Therapeutics.
• Advanced commercialization of Winrevair, a major new growth driver in pulmonary arterial hypertension.
• Built growth platforms in cardiovascular disease, immunology, pulmonary medicine, HIV, and vaccines.
• Accelerated pipeline diversification to reduce reliance on oncology revenue.

Why Contract Pharma Readers Should Care

Merck’s biologics expansion and late-stage pipeline diversification are likely to drive future manufacturing, development, and outsourcing activity.

---

3. Dr. Thomas Schinecker

CEO, Roche Group

CEO since: 2023

Why He Matters

A lifelong Roche executive, Thomas Schinecker is steering the company into new growth areas while balancing Roche’s traditional strengths in oncology, diagnostics, and biologics.

Career Path

Schinecker joined Roche in 2003 through its international management development program and advanced through numerous leadership positions in Roche Diagnostics. He became CEO of Roche Diagnostics in 2019 and CEO of Roche Group in March 2023.

At a Glance

Background: Molecular biology, diagnostics, international operations
Strategic focus: Obesity, neuroscience, diagnostics innovation

Key Achievements

• Led Roche’s acquisition of Carmot Therapeutics.
• Established Roche’s entry into the obesity market through CT-388 and related assets.
• Prioritized investment in obesity and neuroscience while discontinuing lower-priority programs.
• Continued growth of blockbuster ophthalmology drug Vabysmo.

Why Contract Pharma Readers Should Care

Roche’s expansion into obesity and biologics is expected to increase demand for development, manufacturing, and supply-chain partnerships.

---

4. Dr. Albert Bourla

Chairman and CEO, Pfizer

CEO since: 2019

Why He Matters

Albert Bourla has led Pfizer through one of the most consequential periods in pharmaceutical history, including the COVID-19 pandemic and the company’s subsequent transformation into a more innovation-driven biopharmaceutical organization.

Career Path

A Pfizer veteran of more than three decades, Bourla held leadership positions across multiple countries and business units before becoming CEO in January 2019.

At a Glance

Background: Scientific research, vaccines, global operations
Strategic focus: Oncology, vaccines, innovation, AI-enabled drug development

Key Achievements

• Oversaw development of the Pfizer-BioNTech COVID-19 vaccine and Paxlovid.
• Completed the $43 billion acquisition of Seagen.
• Expanded Pfizer’s oncology and antibody-drug conjugate (ADC) capabilities.
• Strengthened the pipeline through acquisitions including Arena Pharmaceuticals, Biohaven, and Global Blood Therapeutics.

Why Contract Pharma Readers Should Care

Pfizer’s growing oncology presence and ADC strategy are driving demand for specialized development and manufacturing capabilities.

---

5. Robert A. Michael

Chairman of the Board and CEO, AbbVie

CEO since: 2024

Why He Matters

Robert Michael took over leadership at a pivotal moment as AbbVie navigated the post-Humira era while pursuing growth through immunology, neuroscience, and oncology.

Career Path

A longtime AbbVie and Abbott executive, Michael has held leadership roles in finance, operations, corporate strategy, and commercial management before becoming CEO in 2024.

At a Glance

Background: Finance, operations, corporate strategy
Strategic focus: Immunology, neuroscience, oncology

Key Achievements

• Accelerated growth of Skyrizi and Rinvoq as successors to Humira.
• Completed AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics.
• Expanded AbbVie’s neuroscience pipeline in schizophrenia, Parkinson’s disease, and mood disorders.
• Strengthened the company’s long-term growth profile beyond Humira.

Why Contract Pharma Readers Should Care

AbbVie’s expanding specialty biologics and neuroscience portfolios are increasing demand for advanced development and manufacturing services.

---

6. Joaquin Duato

Chairman and CEO, Johnson & Johnson

CEO since: 2022

Why He Matters

Joaquin Duato has reshaped Johnson & Johnson into a focused pharmaceutical and MedTech organization while accelerating investment in oncology, cardiovascular disease, and advanced therapies.

Career Path

Duato spent four decades at Johnson & Johnson in leadership roles across geographies, functions, and operating companies before becoming CEO in 2022 and chairman in 2023.

At a Glance

Background: International operations, pharmaceuticals, MedTech
Strategic focus: Oncology, cardiovascular disease, cell therapy, MedTech

Key Achievements

• Completed the separation of Kenvue.
• Expanded the MedTech business through acquisitions including Shockwave Medical and Abiomed.
• Advanced CARVYKTI and other cell therapy programs.
• Increased focus on innovative medicines and medical technology.

Why Contract Pharma Readers Should Care

Johnson & Johnson remains a major player in cell therapy, advanced manufacturing, and high-growth MedTech markets.

---

7. Pascal Soriot

Executive Director and CEO, AstraZeneca

CEO since: 2012

Why He Matters

Pascal Soriot is widely credited with overseeing one of the most impressive turnarounds in the pharmaceutical industry, transforming AstraZeneca from a company facing a patent cliff into a global innovation leader.

Career Path

Before joining AstraZeneca in 2012, Soriot served as CEO of Genentech and chief operating officer of Roche’s pharmaceutical division.

At a Glance

Background: R&D, oncology, global leadership
Strategic focus: Oncology, rare diseases, biologics

Key Achievements

• Rebuilt AstraZeneca following a major patent cliff.
• Established Tagrisso as a leading treatment for EGFR-mutated lung cancer.
• Completed the $39 billion acquisition of Alexion Pharmaceuticals.
• Oversaw development and global distribution of the Oxford-AstraZeneca COVID-19 vaccine.
• Expanded the company’s oncology leadership through Enhertu and other targeted therapies.

Why Contract Pharma Readers Should Care

AstraZeneca remains one of the industry’s largest investors in biologics, oncology manufacturing, ADC development, and advanced therapies.

---

8. Vasant Narasimhan, M.D.

CEO, Novartis

CEO since: 2018

Why He Matters

Vas Narasimhan has transformed Novartis into a focused innovative medicines company while emphasizing advanced technology platforms and digital transformation.

Career Path

Since joining Novartis in 2005, Narasimhan has held leadership positions across vaccines, development, and drug development before becoming CEO in 2018.

At a Glance

Background: Physician-scientist, drug development, global health
Strategic focus: Radioligand therapy, neuroscience, oncology, cardiovascular disease

Key Achievements

• Led the spin-offs of Alcon and Sandoz.
• Established Novartis as a leader in radioligand therapy through Pluvicto and Lutathera.
• Expanded cell and gene therapy capabilities.
• Built a more focused innovative medicines business with strong growth products.

Why Contract Pharma Readers Should Care

Radiopharmaceutical manufacturing and advanced therapy production are becoming increasingly important areas of industry investment and outsourcing.

---

9. Belén Garijo

CEO, Sanofi

CEO since: 2026

Why She Matters

Belén Garijo brings extensive pharmaceutical leadership experience to Sanofi as the company seeks to strengthen its innovative medicines portfolio and execute its next phase of growth.

Career Path

Prior to joining Sanofi as CEO, Garijo served as CEO of Merck and previously held senior leadership roles at Sanofi-Aventis and within the healthcare industry.

At a Glance

Background: Clinical pharmacology, R&D, global operations
Strategic focus: Immunology, neurology, specialty medicines

Key Achievements

• Oversaw the approval of Cenrifki for secondary progressive multiple sclerosis.
• Strengthened focus on R&D productivity and portfolio prioritization.
• Continued expansion of Sanofi’s neurology and immunology franchises.
• Advanced strategy around next-generation growth drivers beyond Dupixent.

Why Contract Pharma Readers Should Care

Sanofi’s growing presence in specialty medicines, immunology, and neurology is expected to generate new manufacturing and development opportunities.

---

10. Maziar Mike Doustdar

President and CEO, Novo Nordisk

CEO since: 2025

Why He Matters

Maziar Mike Doustdar assumed leadership as Novo Nordisk entered a new phase of competition in the obesity and diabetes markets, with increasing emphasis on next-generation therapies and global supply expansion.

Career Path

Doustdar joined Novo Nordisk in 1992 and advanced through finance, logistics, operations, marketing, and international leadership roles before becoming CEO in 2025.

At a Glance

Background: Commercial operations, emerging markets, international leadership
Strategic focus: Obesity, diabetes, cardiometabolic disease

Key Achievements

• Expanded the reach of the Wegovy franchise, including oral semaglutide.
• Advanced development of CagriSema, Novo’s leading next-generation obesity treatment.
• Continued investment in obesity and cardiometabolic innovation.
• Managed Novo’s response to increasing competition in the GLP-1 market.

Why Contract Pharma Readers Should Care

Novo Nordisk’s demand for obesity-drug manufacturing capacity continues to influence supply-chain strategy, fill-finish capacity, and API production across the industry.